新药三期临床试验结果未达预期

$Array生物制药(ARRY)$ 盘前跌这么多，傻眼了。。

#公司快讯#

大公司头条

大公司又发生了什么事，收购、合作、入股？来这里关注最重要的商业新闻和公司动向吧

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

鼓谜
2016-08-09
鼓谜
阿斯利康的三期临床试验提供了更新Selumetinib在非小细胞肺癌

2016年8月09年,

Selumetinib不符合审判端点KRASm NSCLC患者的无进展生存

科罗拉多州博尔德,8月。2016年9日——阿斯利康(经度/ STO /纽交所:下跌)今天宣布结果的三期选择1试验MEK抑制剂,1/2 selumetinib,结合多烯紫杉醇化疗2 nd-line治疗患者的KRAS mutat
- 哗哗哗:
  比解放前还前
- Kyle:
  一夜回到解放前
- 葡萄烟:
  一夜回到解放前
财报哥
2016-08-09
财报哥
总有药股想害朕…

发表看法

5

3

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":23629,"tweetId":"23629","gmtCreate":1470730676550,"gmtModify":1704872415808,"author":{"id":172865062005960,"authorId":172865062005960,"authorIdStr":"172865062005960","name":"六指魔","avatar":"https://static.laohu8.com/80312cf257e1943f848491859e5b65a1","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[{"themeId":"88d7294d91bb46649fa7d789f49a604b","categoryId":"bc7f9e79615545918dda2e7d7cfb9e15","name":"大公司头条","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":88d7294d91bb46649fa7d789f49a604b}&rnconfig={\"headerBarHidden\": true}","description":"大公司又发生了什么事，收购、合作、入股？来这里关注最重要的商业新闻和公司动向吧","image":"https://static.tigerbbs.com/326e1931a7b7ea2f2b045918f3ea1bc5"}],"images":[],"coverImages":[],"title":"新药三期临床试验结果未达预期","extraTitle":"","html":"<html><head></head><body><p>$Array生物制药(ARRY)$ 盘前跌这么多，傻眼了。。</p> <p>#公司快讯#</p></body></html>","htmlText":"<html><head></head><body><p>$Array生物制药(ARRY)$ 盘前跌这么多，傻眼了。。</p> <p>#公司快讯#</p></body></html>","text":"$Array生物制药(ARRY)$ 盘前跌这么多，傻眼了。。 #公司快讯#","highlighted":1,"essential":1,"paper":2,"likeSize":3,"commentSize":5,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/23629","repostId":0,"isVote":1,"tweetType":1,"viewCount":1413,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["ARRY"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":52,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":169451,"gmtCreate":1470731138969,"gmtModify":1470731138969,"authorId":112284157742196,"author":{"id":112284157742196,"authorId":112284157742196,"name":"鼓谜","avatar":"https://static.tigerbbs.com/f08906fb70bff53c4cb0e84ae60cde4b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":23629,"type":1,"supId":0,"prevId":0,"content":"阿斯利康的三期临床试验提供了更新Selumetinib在非小细胞肺癌\n<br>\n<br>2016年8月09年,\n<br>\n<br>Selumetinib不符合审判端点KRASm NSCLC患者的无进展生存\n<br>\n<br>科罗拉多州博尔德,8月。2016年9日——阿斯利康(经度/ STO /纽交所:下跌)今天宣布结果的三期选择1试验MEK抑制剂,1/2 selumetinib,结合多烯紫杉醇化疗2 nd-line治疗患者的KRAS mutat","text":"阿斯利康的三期临床试验提供了更新Selumetinib在非小细胞肺癌\n<br>\n<br>2016年8月09年,\n<br>\n<br>Selumetinib不符合审判端点KRASm NSCLC患者的无进展生存\n<br>\n<br>科罗拉多州博尔德,8月。2016年9日——阿斯利康(经度/ STO /纽交所:下跌)今天宣布结果的三期选择1试验MEK抑制剂,1/2 selumetinib,结合多烯紫杉醇化疗2 nd-line治疗患者的KRAS mutat","html":"阿斯利康的三期临床试验提供了更新Selumetinib在非小细胞肺癌\n<br>\n<br>2016年8月09年,\n<br>\n<br>Selumetinib不符合审判端点KRASm NSCLC患者的无进展生存\n<br>\n<br>科罗拉多州博尔德,8月。2016年9日——阿斯利康(经度/ STO /纽交所:下跌)今天宣布结果的三期选择1试验MEK抑制剂,1/2 selumetinib,结合多烯紫杉醇化疗2 nd-line治疗患者的KRAS mutat","likeSize":1,"commentSize":3,"subComments":[{"id":169469,"gmtCreate":1470733453095,"gmtModify":1470733453095,"authorId":9927482922823,"author":{"id":9927482922823,"authorId":9927482922823,"name":"哗哗哗","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":23629,"type":1,"supId":169451,"prevId":0,"content":"比解放前还前","text":"比解放前还前","html":"比解放前还前"},{"id":169467,"gmtCreate":1470733377037,"gmtModify":1470733377037,"authorId":16184556781368,"author":{"id":16184556781368,"authorId":16184556781368,"name":"Kyle","avatar":"https://static.laohu8.com/acc549adc7247716e2142e087a6d55e1","vip":1,"currentWearingBadge":{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.23","exceedPercentage":"93.63%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"hat":"https://static.tigerbbs.com/5c5b6ed6e3b5dcb14f9ef3ceb365e412","crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":23629,"type":1,"supId":169451,"prevId":0,"content":"一夜回到解放前","text":"一夜回到解放前","html":"一夜回到解放前"},{"id":169462,"gmtCreate":1470732532045,"gmtModify":1470732532045,"authorId":64590842003160,"author":{"id":64590842003160,"authorId":64590842003160,"name":"葡萄烟","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":23629,"type":1,"supId":169451,"prevId":0,"content":"一夜回到解放前","text":"一夜回到解放前","html":"一夜回到解放前"}],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":169573,"gmtCreate":1470740890834,"gmtModify":1470740890834,"authorId":146780470149060,"author":{"id":146780470149060,"authorId":146780470149060,"name":"财报哥","avatar":"https://static.laohu8.com/9048975d6094785e05b5693c2a24a510","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":23629,"type":1,"supId":0,"prevId":0,"content":"总有药股想害朕…","text":"总有药股想害朕…","html":"总有药股想害朕…","likeSize":2,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/23629"}